Pioneers in Neuroscience

REGARDING OUR ADUCANUMAB ANNOUNCEMENT

On October 22, 2019, Biogen announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer’s disease.

Read the full press release.

Learn more about the aducanumab announcement.

For investor inquiries related to this announcement, please contact Biogen Investor Relations at IR@biogen.com.

We are Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. 

Our focus

We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience.

10/22/19 6:50 AM EDT
Biogen Reports Q3 2019 Revenues of $3.6 Billion
View all news
Regarding Our Nightstar Therapeutics Acquisition

On June 7, 2019, Biogen completed its acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.

Read the full press release.
Learn more about our Scientific Expertise and Pipeline.

For investor inquiries related to the Nightstar Therapeutics acquisition, please contact Biogen Investor Relations at IR@biogen.com.

Our People

Meet Tennille.

Tennille works in our Patient Services group in Research Triangle Park in North Carolina.

Follow us on social media